Fundamental Analysis of ENVERIC BIOSCIENCES INC(NASDAQ:ENVB) stock

Fundamental Rating

Overall ENVB gets a fundamental rating of 2 out of 10. We evaluated ENVB against 192 industry peers in the Pharmaceuticals industry. The financial health of ENVB is average, but there are quite some concerns on its profitability. ENVB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ENVB had negative earnings in the past year.

ENVB had a negative operating cash flow in the past year.

ENVB had negative earnings in each of the past 5 years.

In the past 5 years ENVB always reported negative operating cash flow.

1.2 Ratios

ENVB has a worse Return On Assets (-205.75%) than 89.67% of its industry peers.

ENVB has a worse Return On Equity (-249.45%) than 73.91% of its industry peers.

		Industry Rank	Sector Rank
ROA	-205.75%
ROE	-249.45%
ROIC	N/A

ROA(3y)-228.5%

ROA(5y)-175.33%

ROE(3y)-413.37%

ROE(5y)-299.5%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ENVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for ENVB has been increased compared to 1 year ago.

ENVB has more shares outstanding than it did 5 years ago.

ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -32.27, we must say that ENVB is in the distress zone and has some risk of bankruptcy.

ENVB has a worse Altman-Z score (-32.27) than 90.22% of its industry peers.

There is no outstanding debt for ENVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-32.27

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ENVB has a Current Ratio of 5.17. This indicates that ENVB is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of ENVB (5.17) is better than 66.30% of its industry peers.

A Quick Ratio of 5.17 indicates that ENVB has no problem at all paying its short term obligations.

ENVB has a Quick ratio of 5.17. This is in the better half of the industry: ENVB outperforms 68.48% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.17
Quick Ratio	5.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ENVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.04%, which is quite impressive.

EPS 1Y (TTM)76.04%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.54%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.32% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y74.54%

EPS Next 2Y35.18%

EPS Next 3Y21.32%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ENVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENVB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ENVB's earnings are expected to grow with 21.32% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.18%

EPS Next 3Y21.32%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ENVB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (1/8/2025, 8:00:01 PM)

After market: 0.39 -0.03 (-6.23%)

0.4159

-0.09 (-17.63%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-14 2024-11-14/amc

Earnings (Next)N/A N/A

Inst Owners5.67%

Inst Owner Change0%

Ins Owners6.63%

Ins Owner Change15.77%

Market Cap4.23M

Analysts82.86

Price Target8.49 (1941.36%)

Short Float %1.68%

Short Ratio0.64

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)55.09%

Min EPS beat(2)54.75%

Max EPS beat(2)55.44%

EPS beat(4)4

Avg EPS beat(4)34.94%

Min EPS beat(4)6.72%

Max EPS beat(4)55.44%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)18.37%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.07
P/tB	1.09
EV/EBITDA	N/A

EPS(TTM)-2.57

EYN/A

EPS(NY)-1.44

Fwd EYN/A

FCF(TTM)-0.8

FCFYN/A

OCF(TTM)-0.8

OCFYN/A

SpS0

BVpS0.39

TBVpS0.38

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-205.75%
ROE	-249.45%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-228.5%

ROA(5y)-175.33%

ROE(3y)-413.37%

ROE(5y)-299.5%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.17
Quick Ratio	5.17
Altman-Z	-32.27

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)103.19%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)76.04%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.54%

EPS Next Y74.54%

EPS Next 2Y35.18%

EPS Next 3Y21.32%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y53.16%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year25.01%

EBIT Next 3YN/A

EBIT Next 5Y14.36%

FCF growth 1Y57.46%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y53.98%

OCF growth 3YN/A

OCF growth 5YN/A

ENVERIC BIOSCIENCES INC (ENVB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens